FRACTURE RISK IN WOMEN ≥65 YEARS WITH ONCE-MONTHLY ORAL IBANDRONATE COMPARED WITH WEEKLY BISPHOSPHONATES: SUBANALYSIS FROM THE EVALUATION OF IBANDRONATE EFFICACY (VIBE) DATABASE STUDY

被引：0
|
作者：
Silverman, S. [1 ]
Poston, S. [2 ]
Blumentals, W. [3 ]
Reginster, J. -Y. [4 ]
机构：
[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Beverly Hills, CA USA
[2] GlaxoSmithKline, Res Triangle Pk, NC USA
[3] Roche, Nutley, NJ USA
[4] Univ Liege, Bone & Cartilage Metab Unit, Liege, Belgium
来源：
OSTEOPOROSIS INTERNATIONAL | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：153 / 153
页数：1
相关论文
共 34 条
  • [31] A CANDIDATE INDENTIFICATION QUESTIONNAIRE FOR PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS SWITCHED FROM TREATMENT WITH A DIALY OR WEEKLY BISHPOSPHONATE TO ONCE-MONTHLY IBANDRONATE-BONCURE: RESULTS OF TURKISH SUB-STUDY
    Eskiyurt, Nurten
    Sendur, Omer Faruk
    Yalcin, Peyman
    Oncel, Sema
    Saridogan, Merih
    Sarpel, Tunay
    Tosun, Mehmet
    Kutsal, Yesim Gokce
    Senel, Kazim
    Gursoy, Savas
    Canturk, Ferhan
    Irdesel, Jale
    Demir, Huseyin
    Ozdener, Fatih
    Oncel, Hakan
    Serpici, Vesile
    Ugurlu, Hatice
    Kirazli, Yesim
    Ardic, Fusun
    Butun, Bulent
    Akyuz, Gulseren
    Cerrahoglu, Lale
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 198 - 198
  • [32] MONTHLY ORAL IBANDRONATE FOR REDUCTION OF FRACTURE RISK IN POSTMENOPAUSAL OSTEOPOROSIS: ANALYSIS OF DATA FROM META-ANALYSES, RANDOMIZED CLINICAL TRIALS, AND OBSERVATIONAL CLAIMS DATABASE
    Silverman, Stuart L.
    Sunyecz, John A.
    Barr, Charles E.
    Miller, Paul D.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S198 - S198
  • [33] Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate
    Brown, J. P.
    Roux, C.
    Ho, P. R.
    Bolognese, M. A.
    Hall, J.
    Bone, H. G.
    Bonnick, S.
    van den Bergh, J. P.
    Ferreira, I.
    Dakin, P.
    Wagman, R. B.
    Recknor, C.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 (07) : 1953 - 1961
  • [34] Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate
    J. P. Brown
    C. Roux
    P. R. Ho
    M. A. Bolognese
    J. Hall
    H. G. Bone
    S. Bonnick
    J. P. van den Bergh
    I. Ferreira
    P. Dakin
    R. B. Wagman
    C. Recknor
    Osteoporosis International, 2014, 25 : 1953 - 1961
1234